NocTURNA – Nanotechnology for mRNA Encapsulation in Tuberculosis Vaccines

Overview

This project has been subsidised by the CDTI (“subvencionado por el CDTI”).

It is funded by:

  • Ministry of Science, Innovation and Universities
  • European Union – Next Generation EU
  • Recovery, Transformation and Resilience Plan (PRTR)
  • CDTI

Objectives

NOCTURNA aims to develop a nanoencapsulation platform for mRNA-based vaccination against tuberculosis (TB). The need for a safe and effective vaccine is imperative to control this disease. This technology seeks to significantly improve vaccine stability and efficacy, enabling a more robust and long-lasting immune response, as well as adaptable dosing strategies suited for administration across diverse geographic regions with varying socioeconomic contexts.

This project, led by DIVERSA Technologies, will be carried out in close collaboration with Paulo Bettencourt from the Universidade Católica Portuguesa, a renowned researcher in the field of immunology and vaccinology. His extensive experience and leadership in the development of mRNA vaccines, particularly against infectious diseases such as tuberculosis and malaria, will be key to the success of this initiative.

This project represents a strong commitment by DIVERSA Technologies to industrial research for the development and commercialization of innovative solutions addressing some of the most urgent challenges in global health.

Consortium members

  • DIVERSA Technologies
  • Universidade Católica Portuguesa

Funding

  • Programme: Proyectos “Multi-País” 2024, vinculados al PERTE de Salud de Vanguardia.
  • Grant reference: [PAIS-20241074]
  • Funding body: CDTI
  • Amount funded: 296.404,50 €.

Acknowledgment

This project has been funded by the Ministry of Science, Innovation and Universities and by the CDTI, with support from the European Union – Next Generation EU, within the framework of the Recovery, Transformation and Resilience Plan.

Logos